Innovative therapeutics

Investors

IR Snapshot

NASDAQBMRN
Beta1.67
Shares Outstanding172.9M
Average Volume (10 days)1.0M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($3.84)
Sales (TTM)$6.46
Book Value (MRQ)$16.00
Cash Flow (TTM)($1.37)
Cash (MRQ)$4.59

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy12
 
Buy2
 
Hold3
 
Underperform0
 
Sell0
 

Recent Insider Transactions

G. Eric Davis
EVP, General Counsel
(2,238)
Sell
Mar 16, 2017
Brian Mueller
SVP, Corporate Controller
(376)
Dispose
Mar 16, 2017
Daniel K. Spiegelman
EVP, Chief Financial Officer
(1,989)
Sell
Mar 16, 2017
Jean-Jacques Bienaime
Director, Chief Executive Officer
(5,000)
Sell
Mar 16, 2017
Jean-Jacques Bienaime
Director, Chief Executive Officer
(15,690)
Dispose
Mar 15, 2017

Recent SEC Filings

Insider Buy/Sell
Mar 24, 2017
Insider Buy/Sell
Mar 24, 2017
Insider Buy/Sell
Mar 24, 2017
Insider Buy/Sell
Mar 24, 2017
Insider Buy/Sell
Mar 24, 2017

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI) PKU, LEMS

Products

Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information